Literature DB >> 11462178

Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization.

M Webb1, L W Riley, R B Roberts.   

Abstract

The increase in costs of hospitalization for patients with drug-resistant infection may be associated with drug resistance itself or with the severity of the underlying illness that predisposes patients to acquire the drug-resistant infection. To address this issue, risk factors and cost of hospitalization were compared for patients infected or colonized with vancomycin-susceptible Enterococcus faecium (VSEF) or vancomycin-resistant E. faecium (VREF) in a large tertiary-care hospital in New York City. From January 1995 through December 1996, 157 patients with VSEF and 262 patients with VREF were identified. CMI (case-mix index) was assigned to each patient as a measure of severity of illness, with a CMI of 1 considered to represent illness of average severity. For all patients who were assigned a CMI of <3, the cost per day of hospitalization for patients with VREF was significantly greater than that for patients with VSEF. However, for patients with a CMI of >3, there was no difference between cost of hospitalization for patients with VREF and that for patients with VSEF. These observations indicate that, although vancomycin resistance is associated with an increased cost of hospitalization for less severely ill patients with VREF, patients with severe underlying illness, regardless of vancomycin resistance, incur similar hospitalization costs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11462178     DOI: 10.1086/321891

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  [Prevention and control of the spread of vancomycin-resistant enterococci: results of a workshop held by the German Society for Hygiene and Microbiology].

Authors:  R-P Vonberg; I F Chaberny; A Kola; F Mattner; S Borgmann; M Dettenkofer; D Jonas; A-M Fahr; I Klare; G Werner; K Weist; C Wendt; P Gastmeier
Journal:  Anaesthesist       Date:  2007-02       Impact factor: 1.041

Review 2.  Factors associated with variation in estimates of the cost of resistant infections.

Authors:  Bevin Cohen; Elaine L Larson; Patricia W Stone; Matthew Neidell; Sherry A Glied
Journal:  Med Care       Date:  2010-09       Impact factor: 2.983

Review 3.  Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time.

Authors:  Marin Kollef
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Evaluation of a novel chromogenic agar medium for isolation and differentiation of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis isolates.

Authors:  Nathan A Ledeboer; Kingshuk Das; Michael Eveland; Céline Roger-Dalbert; Sandrine Mailler; Sonia Chatellier; William Michael Dunne
Journal:  J Clin Microbiol       Date:  2007-02-28       Impact factor: 5.948

5.  Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort.

Authors:  Anne M Butler; Margaret A Olsen; Liana R Merz; Rebecca M Guth; Keith F Woeltje; Bernard C Camins; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2010-01       Impact factor: 3.254

6.  Novel chromogenic medium for detection of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis.

Authors:  Gaëlle Cuzon; Thierry Naas; Nicolas Fortineau; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

7.  The costs of nosocomial resistant gram negative intensive care unit infections among patients with the systemic inflammatory response syndrome- a propensity matched case control study.

Authors:  Anupama Vasudevan; Babar Irfan Memon; Amartya Mukhopadhyay; Jialiang Li; Paul Ananth Tambyah
Journal:  Antimicrob Resist Infect Control       Date:  2015-02-02       Impact factor: 4.887

8.  Economic burden of nosocomial infections caused by vancomycin-resistant enterococci.

Authors:  Laura Puchter; Iris Freya Chaberny; Frank Schwab; Ralf-Peter Vonberg; Franz-Christoph Bange; Ella Ebadi
Journal:  Antimicrob Resist Infect Control       Date:  2018-01-05       Impact factor: 4.887

9.  Healthcare-associated vancomycin resistant Enterococcus faecium infections in the Mansoura University Hospitals intensive care units, Egypt.

Authors:  Dalia Moemen; Doaa Tawfeek; Wafaa Badawy
Journal:  Braz J Microbiol       Date:  2015-07-01       Impact factor: 2.476

10.  Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia.

Authors:  Agnes Loo Yee Cheah; Trisha Peel; Benjamin P Howden; Denis Spelman; M Lindsay Grayson; Roger L Nation; David C M Kong
Journal:  BMC Infect Dis       Date:  2014-06-28       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.